At study days 0 and 56, macaques were immunized i.m. with 4 × 107 PFU of the quadrivalent vaccine or rVSV N4CT1-HIVgag as control. At study day 84, macaques were challenged i.m. with 1000 PFU (A) LASV (strain 0043/LV/14), (B) EBOV (strain Kikwit), (C) SUDV (strain Gulu), or (D) MARV (strain Angola), and monitored up to 28 days.